Telomir Pharmaceuticals, Inc. $TELO Stake Cut by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. cut its position in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 36.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,282 shares of the company’s stock after selling 18,248 shares during the quarter. Goldman Sachs Group Inc. owned 0.11% of Telomir Pharmaceuticals worth $104,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE increased its position in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after buying an additional 10,880 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Telomir Pharmaceuticals by 279.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,699 shares of the company’s stock worth $44,000 after buying an additional 7,879 shares during the period. Nuveen Asset Management LLC acquired a new stake in Telomir Pharmaceuticals in the fourth quarter worth $103,000. Bank of New York Mellon Corp increased its position in Telomir Pharmaceuticals by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 91,353 shares of the company’s stock worth $295,000 after buying an additional 19,058 shares during the period. Finally, Nuveen LLC acquired a new stake in Telomir Pharmaceuticals in the first quarter worth $81,000.

Telomir Pharmaceuticals Stock Performance

Shares of TELO opened at $1.34 on Tuesday. The firm has a market capitalization of $43.26 million, a price-to-earnings ratio of -2.48 and a beta of -0.72. Telomir Pharmaceuticals, Inc. has a one year low of $1.12 and a one year high of $7.08. The stock’s fifty day moving average is $1.56 and its 200-day moving average is $2.09.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.09). Analysts forecast that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current fiscal year.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.